Loading clinical trials...
Loading clinical trials...
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
Conditions
Interventions
4D-125 IVT Injection
Observational
Locations
8
United States
University of Colorado
Aurora, Colorado, United States
Vitreo Retinal Associates
Gainesville, Florida, United States
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, United States
Columbia University Medical Center/Edward Harkness Eye Institute
New York, New York, United States
Duke University Eye Center/Dept. of Ophthalmology
Durham, North Carolina, United States
Casey Eye Institute, Oregon Health and Science University
Portland, Oregon, United States
Start Date
June 9, 2020
Primary Completion Date
June 1, 2026
Completion Date
May 1, 2029
Last Updated
March 21, 2025
NCT07174726
NCT06492850
NCT06646289
NCT04850118
NCT03314207
Lead Sponsor
4D Molecular Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions